Recent advances through a better understanding of the molecular mechanisms involved in the pathogenesis of RCC have resulted in the development of drugs that target angiogenesis by either directly inhibiting vascular endothelial growth factor (VEGF)-mediated signalling or indirectly by inhibiting the mammalian target of rapamycin downstream (7). The gene discussed is VEGFA; the disease is renal cell carcinoma.